153 related articles for article (PubMed ID: 24715244)
1. Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.
Heiduschka G; Grah A; Oberndorfer F; Seemann R; Kranz A; Kornek G; Wrba F; Thurnher D; Selzer E
Strahlenther Onkol; 2014 Sep; 190(9):832-8. PubMed ID: 24715244
[TBL] [Abstract][Full Text] [Related]
2. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
[TBL] [Abstract][Full Text] [Related]
3. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
4. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
Chung CH; Zhang Q; Kong CS; Harris J; Fertig EJ; Harari PM; Wang D; Redmond KP; Shenouda G; Trotti A; Raben D; Gillison ML; Jordan RC; Le QT
J Clin Oncol; 2014 Dec; 32(35):3930-8. PubMed ID: 25267748
[TBL] [Abstract][Full Text] [Related]
5. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
[TBL] [Abstract][Full Text] [Related]
7. High-grade acute organ toxicity and p16(INK4A) expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma.
Tehrany N; Kitz J; Rave-Fränk M; Lorenzen S; Li L; Küffer S; Hess CF; Burfeind P; Reichardt HM; Canis M; Beissbarth T; Wolff HA
Strahlenther Onkol; 2015 Jul; 191(7):566-72. PubMed ID: 25575976
[TBL] [Abstract][Full Text] [Related]
8. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
[TBL] [Abstract][Full Text] [Related]
9. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation.
Broglie MA; Soltermann A; Rohrbach D; Haile SR; Pawlita M; Studer G; Huber GF; Moch H; Stoeckli SJ
Head Neck; 2013 Dec; 35(12):1698-706. PubMed ID: 23508511
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus in metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma.
Compton AM; Moore-Medlin T; Herman-Ferdinandez L; Clark C; Caldito GC; Wang XI; Thomas J; Abreo FW; Nathan CO
Otolaryngol Head Neck Surg; 2011 Jul; 145(1):51-7. PubMed ID: 21493313
[TBL] [Abstract][Full Text] [Related]
11. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
12. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
13. Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.
Heiduschka G; Grah A; Oberndorfer F; Kadletz L; Altorjai G; Kornek G; Wrba F; Thurnher D; Selzer E
Strahlenther Onkol; 2015 Mar; 191(3):209-16. PubMed ID: 25252603
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
16. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma.
Barber BR; Biron VL; Klimowicz AC; Puttagunta L; Côté DW; Seikaly H
J Otolaryngol Head Neck Surg; 2013 Oct; 42(1):53. PubMed ID: 24401183
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
